Abstract: A truncated form of ?? chain (e??), the soybean 7S globulin, active in controlling the cholesterol and triglyceride homeostasis in in vitro and in vivo models, was cloned and expressed in the yeast Pichia pastoris. The recombinant polypeptide spanned 142 amino acid residues from the N-terminal side and included the N-terminal extension region of the soybean alpha? subunit. The e?? polypeptide was purified by conventional biochemical techniques and its potential to modulate the activity of the LDL-receptor was evaluated in a human hepatoma cell line (Hep G2) by monitoring the uptake and degradation of labeled LDL.

Abstract: A purified amino-terminal polypeptide fragment of the soy ?-conglycinin ?? subunit is prepared by selective extraction of defatted soy with an aqueous solution of sodium bisulfite, precipitation with ethanol, and Metal Affinity Chromatography (MAC) under denaturing conditions to obtain the ?? subunit. The ?? subunit is then enzymatically treated with chymotrypsin and subjected to further MAC to recover the amino-terminal fragment of the polypeptide (MW 28,000 Da).

Abstract: A truncated form of ?? chain (e??), the soybean 7S globulin, active in controlling the cholesterol and triglyceride homeostasis in in vitro and in vivo models, was cloned and expressed in the yeast Pichia pastoris. The recombinant polypeptide spanned 142 amino acid residues from the N-terminal side and included the N-terminal extension region of the soybean alpha? subunit. The e?? polypeptide was purified by conventional biochemical techniques and its potential to modulate the activity of the LDL-receptor was evaluated in a human hepatoma cell line (Hep G2) by monitoring the uptake and degradation of labeled LDL.

Abstract: A purified amino-terminal polypeptide fragment of the soy ?-conglycinin ?? subunit is prepared by selective extraction of defatted soy with an aqueous solution of sodium bisulfite, precipitation with ethanol, and Metal Affinity Chromatography (MAC) under denaturing conditions to obtain the ?? subunit. The ?? subunit is then enzymatically treated with chymotrypsin and subjected to further MAC to recover the amino-terminal fragment of the polypeptide (MW 28,000 Da).

Abstract: A process for the extraction, purification and enzymatic modification of ?-conglycinin ?? subunit, wherein ?-conglycinin is selectively extracted from ground, defatted soy, then precipitated by treatment with aqueous ethanol; the enriched fraction is then subjected to Metal Affinity Chromatography (MAC) in denaturant conditions to obtain the ?? subunit, which is treated with chymotrypsin, then subjected to a further MAC to recover the amino-terminal region of this polypeptide (MW 28,000 Da).

Abstract: A process for the extraction, purification and enzymatic modification of ?-conglycinin ?? subunit, wherein ?-conglycinin is selectively extracted from ground, defatted soy, then precipitated by treatment with aqueous ethanol; the enriched fraction is then subjected to Metal Affinity Chromatography (MAC) in denaturant conditions to obtain the ?? subunit, which is treated with chymotrypsin, then subjected to a further MAC to recover the amino-terminal region of this polypeptide (MW 28,000 Da).

Abstract: A process for the extraction, purification and enzymatic modification of ?-conglycinin ?? subunit, wherein ?-conglycinin is selectively extracted from ground, defatted soy, then precipitated by treatment with aqueous ethanol; the enriched fraction is then subjected to Metal Affinity Chromatography (MAC) in denaturant conditions to obtain the ?? subunit, which is treated with chymotrypsin, then subjected to a further MAC to recover the amino-terminal region of this polypeptide (MW 28,000 Da).

Abstract: A method for the use of lupin conglutin gamma or of proteins showing homology higher than 50% with lupin conglutin gamma, for the preparation of a medicament, food supplements or foods for the treatment of type II diabetes, pharmaceutical and nutritional compositions containing lupin conglutin gamma, and the use of lupin conglutin gamma as therapeutical agent, in particular as hypoglycemizing agent. Lupin conglutin gamma may be used in pure form or in form of extracts, mixtures or concentrates.

Abstract: A method for the use of lupin conglutin gamma or of proteins showing homology higher than 50% with lupin conglutin gamma, for the preparation of a medicament, food supplements or foods for the treatment of type II diabetes, pharmaceutical and nutritional compositions containing lupin conglutin gamma, and the use of lupin conglutin gamma as therapeutical agent, in particular as hypoglycemizing agent. Lupin conglutin gamma may be used in pure form or in form of extracts, mixtures or concentrates.

Abstract: A process for the extraction, purification and enzymatic modification of ?-conglycinin ?? subunit, wherein ?-conglycinin is selectively extracted from ground, defatted soy, then precipitated by treatment with aqueous ethanol; the enriched fraction is then subjected to Metal Affinity Chromatography (MAC) in denaturant conditions to obtain the ?? subunit, which is treated with chymotrypsin, then subjected to a further MAC to recover the amino-terminal region of this polypeptide (MW 28,000 Da).